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In ambulatory patients with solid cancer, routine thromboprophylaxisto prevent venous thromboembolism is not recommended. Severalrisk prediction scores to identify cancer patients at high risk of
venous thromboembolism have been proposed, but their clinical useful-
ness remains a matter of debate. We evaluated and directly compared
the performance of the Khorana, Vienna, PROTECHT, and CONKO
scores in a multinational, prospective cohort study. Patients with
advanced cancer were eligible if they were due to undergo chemother-
apy or had started chemotherapy in the previous three months. The pri-
mary outcome was objectively confirmed symptomatic or incidental
deep vein thrombosis or pulmonary embolism during a 6-month follow-
up period. A total of 876 patients were enrolled, of whom 260 (30%)
had not yet received chemotherapy. Fifty-three patients (6.1%) devel-
oped venous thromboembolism. The c-statistics of the scores ranged
from 0.50 to 0.57. At the conventional positivity threshold of 3 points,
the scores classified 13-34% of patients as high-risk; the 6-month inci-
dence of venous thromboembolism  in these patients ranged from 6.5%
(95%CI: 2.8-12) for the Khorana score to 9.6% (95%CI: 6.6-13) for the
PROTECHT score. High-risk patients had a significantly increased risk
of venous thromboembolism when using the Vienna (subhazard ratio
1.7; 95%CI: 1.0-3.1) or PROTECHT (subhazard ratio 2.1; 95%CI: 1.2-
3.6) scores. In conclusion, the prediction scores performed poorly in pre-
dicting venous thromboembolism in cancer patients. The Vienna CATS
and PROTECHT scores appear to discriminate better between low- and
high-risk patients, but further improvements are needed before they can
be considered for introduction  into clinical practice.
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ABSTRACT
Introduction
Venous thromboembolism (VTE) complicates the clinical course in 4-5% of can-
cer patients1,2 and is a major cause of morbidity and mortality.3 The management
of VTE in cancer patients is particularly challenging since both the risk of recurrent
VTE and major bleeding are high during anticoagulant treatment. Current interna-
tional guidelines do not recommend routine pharmacological thromboprophylaxis
in ambulatory cancer patients.4-6 Low-molecular weight heparin (LMWH) in pro-
phylactic doses halves the risk of VTE1 and is associated
with an absolute risk reduction of 2-2.5%. However, the
corresponding number needed to treat (40-50) using
thromboprophylaxis is considered too low to justify the
potential increased risk of bleeding and the burden of
daily subcutaneous injections for a prolonged period of
time.4
Risk stratification tools have been developed to identify
a subset of cancer patients in whom the risk of developing
VTE is high enough to justify thromboprophylaxis. The
best validated tool is a score proposed by Khorana and
colleagues7 which aims to identify cancer patients receiv-
ing chemotherapy at high risk of VTE based on the tumor
type, hemoglobin concentration or use of erythropoietin
stimulating agents, white blood cell count, platelet count,
and Body Mass Index (BMI) (Table 1). To improve the dis-
criminatory performance of the Khorana score, others
have proposed modifications by adding biomarker meas-
urements8 or type of chemotherapy,9 or by replacing BMI
with performance status (Table 1).10
Although  these scores performed well in the initial der-
ivation studies, there have either been no subsequent
external validation studies  or those that have been carried
out have reported conflicting results.11-13 Yet, it is important
that performance is maintained across different patient
populations and settings. In addition, scores have not been
directly compared in a large study of representative
patients. To fill this gap, we evaluated and directly com-
pared four clinical prediction scores for VTE in patients
with advanced cancer receiving chemotherapy in a multi-
national cohort study. 
Methods
Study design and patients
Data were collected in a multinational, prospective cohort study
performed in seven hospitals in The Netherlands, Italy, France,
and Mexico, designed to evaluate clinical and laboratory predic-
tors for cancer-associated VTE. Here we report on the perform-
ance of four published clinical prediction scores for cancer-associ-
ated VTE. Outpatients with lung, esophageal, colorectal, pancreat-
ic, breast, prostate, gastric, ovarian, or bladder cancer classified as
stage III or IV according to the American Joint Committee on
Cancer criteria were eligible if they were scheduled for
chemotherapy within seven days or had started chemotherapy in
the previous three months. Exclusion criteria included current pro-
phylactic or therapeutic anticoagulation or adjuvant chemothera-
py. None of the  patients included had received routine thrombo-
prophylaxis in accordance with current guidelines. Patients were
recruited between July 2008 and February 2016. The study was
approved by the institutional review boards of all participating
hospitals. Patients included in the study provided written
informed consent. The study was registered at clinicaltrials.gov
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Figure 1. Cumulative incidence of venous thromboembolism in low- and high-risk patients. Cumulative incidence of venous thromboembolism in patients enrolled
prior to chemotherapy (n=260) who were classified as being at low or high risk of venous thromboembolism by the (A) Khorana score, (B) Vienna CATS score, (C)


















































(identifier: 02095925) after the enrollment of the first patient. The
present report adheres to the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) Statement.14
Study procedures
At baseline, healthcare professionals interviewed patients and
collected baseline clinical and laboratory information from the
medical charts using a standardized case report form. Patients
were enrolled at oncology or vascular medicine departments.
Blood was drawn in 0.109 M citrated tubes via antecubital
venepuncture or through a peripheral catheter shortly after place-
ment. Within one hour after blood collection, platelet poor plasma
was prepared by centrifugation at 1560 g for 20 minutes and
stored at -80°C after snap freezing. 
A follow-up visit was scheduled at 180 days from the clinic visit
by telephone and/or chart review. The primary outcome was the
composite of objectively confirmed symptomatic or incidental
pulmonary embolism (PE), distal or proximal leg deep vein throm-
bosis (DVT), or non-catheter-related upper extremity DVT
(UEDVT), or symptomatic catheter-related UEDVT. VTE was con-
sidered incidental if diagnosed on imaging performed for reasons
other than suspicion of VTE. Incidental events were included in
the primary outcome since current guidelines suggest a treatment
similar to that for symptomatic events. Patients did not undergo
screening for VTE. Imaging reports of all potential outcomes were
verified by 2 of the authors who were blinded to possible predic-
tors of VTE. Deaths were not adjudicated routinely for fatal PE,
but PE was considered to be fatal only if autopsy confirmed PE or
in the case of an objective test positive for PE prior to death. 
Evaluation of prediction scores
We evaluated the following clinical prediction scores for cancer-
associated VTE: the Khorana,7 Vienna CATS,8 PROTECHT,9 and
CONKO scores10 (Table 1). Characteristics of the derivation stud-
ies are provided in the Online Supplementary Appendix text 1.
Evaluation of the Khorana score was included in the initial study
protocol, while the other scores were published during the course
of the study and were subsequently included in the analysis. We
were unable to evaluate a recently proposed genetic risk score.15 In
order to calculate the Vienna CATS score, D-dimer (INNO-
VANCE, Siemens) and soluble P-selectin (ELISA, R&D Systems,
Minneapolis, MN, USA) concentrations were measured centrally
in baseline samples. Analysis of samples of 98 patients from one
center provided implausible results due to incorrect shipment,
forcing us to omit these measurements, while the patients were
retained in the dataset and among the imputed data.
For continuous scores, the overall discriminatory performance
was evaluated. For dichotomized scores, we calculated the pro-
portion of high-risk patients, the cumulative VTE incidence
among high-risk patients, the cumulative VTE incidence among
low-risk patients, and the difference in VTE incidence between
low- and high-risk patients. Since the scores will be used in a
dichotomous fashion in clinical practice by conflating the low and
intermediate groups, we evaluated them at the conventional pos-
itivity threshold of 3 points, and at exploratory positivity thresh-
olds of 2 and 4 points.
Since the derivation of the Khorana, PROTECHT, Vienna CATS,
and CONKO scores was almost entirely based on symptomatic
VTE, a sensitivity analysis restricted to symptomatic events was
performed. Another sensitivity analysis, restricted to the first 90
days of follow up, was performed for comparison with Khorana’s
derivation study which had a median follow up of 2.5 months.7 
Our study was designed to include cancer patients prior to or
within three months of the start of chemotherapy. Since pre-
chemotherapy blood counts are incorporated into all evaluated
clinical prediction scores, we restricted the main analysis to the
group of patients who had not yet received chemotherapy. The
analyses were then repeated in the complete study group, calcu-
lating each score based on pre-chemotherapy blood counts, which
were collected retrospectively at inclusion in patients who had
already started chemotherapy. Results are thus presented for the
group that mirrors cancer patients in whom the decision about
thromboprophylaxis is made prior to chemotherapy and for all
patients, including those for whom the question as to whether to
provide thromboprophylaxis is discussed during the first months
of chemotherapy. 
Assuming a 6-month VTE incidence of 5-6%, the aim was to
enroll approximately 800-1000 patients in order to observe about
50 events, which was considered to be sufficient for multivariable
regression modeling with the five items in the Khorana score. 
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Table 1. Risk prediction scores for venous thromboembolism in cancer patients.
Item Khorana Vienna CATS PROTECHT CONKO 
score score score score
(points) (points) (points) (points)
Pancreatic or gastric cancer (very high-risk tumors) +2 +2 +2 +2
Lung, gynecological, lymphoma, bladder, or testicular (high-risk tumors) +1 +1 +1 +1
Pre-chemotherapy hemoglobin <10 g/dL or use of erythropoietin stimulating agents +1 +1 +1 +1
Pre-chemotherapy white blood cell count >11 x 109/L +1 +1 +1 +1
Pre-chemotherapy platelet count ≥350 x 109/L +1 +1 +1 +1
Body Mass Index >35 kg/m2 +1 +1 +1 -
D-dimer >1.44 mg/L - +1 - -
Soluble P-selectin >53.1 ng/L - +1 - -
Gemcitabine chemotherapy - - +1 -
Platinum-based chemotherapy - - +1 -
WHO performance status ≥2 - - - +1
WHO: World Health Organization. 
Statistical analysis
The cumulative VTE incidence from enrollment to six months
in low- and high-risk patients was estimated using a competing
risk time-to-event analysis in which death was treated as a com-
peting event for VTE. Unlike naïve Kaplan-Meier and Cox
regression analysis, a competing risk analysis does not treat
death as a censored observation, but rather takes into account
that VTE cannot occur after death, thereby providing less biased
estimates.16 Time to VTE was considered censored when
patients underwent cancer surgery with curative intent, started
therapeutic anticoagulation for other reasons than VTE, were
lost to follow up, or at the end of the 6-month follow-up period.
Confidence intervals (CI) at specific time points were calculated
using Choudhury’s method.17
To evaluate the discriminatory performance of the scores, the
time-dependent concordance index (c-index) was calculated while
accounting for death as a competing risk.18 The 95% confidence
intervals were calculated by repeating the analyses in 250 boot-
strap samples. 
To assess the difference in VTE risk between low- and high-risk
patients, subdistribution hazard ratios (SHR) and 95% CIs for the
dichotomized scores were estimated using the competing risks
regression model of Fine and Gray.19 The predictive value of the
separate items in each score was assessed by multivariable com-
peting risks regression models. The proportionality assumption
was checked by adding an interaction term between each variable
and time to the model. 
Multiple imputation was used to minimize the bias associated
with missing data.20 We assumed a 'missing' at random pattern in
which missingness depends on other observed variables. Center,
inclusion year, all baseline characteristics, and outcome data were
included in the imputation model to create twenty imputed
datasets. Analyses were performed separately in each imputed
dataset; estimates with standard errors were combined across the
datasets using Rubin’s rule.21 The complete case analyses were
provided for comparison. 
A significance level of 0.05 was used in statistical testing. All
analyses were performed in R, v.3.3.2 (R Foundation for Statistical
Computing, Vienna, Austria; www.R-project.org), in particular using
the “mice” v.2.25 package for multiple imputation, the “cmprsk”
v.2.2-7 for the competing risk analyses, and the “pec” package
v.2.4.9 for the time-dependent c-indices. 
Results
During the 7.5-year study period, 876 patients with
stage III or IV solid cancer were enrolled, of whom 260
(30%) had not yet started chemotherapy. The mean age
was 64 years; 59% of patients were male. Baseline charac-
Predicting cancer-associated venous thromboembolism
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Table 2. Baseline characteristics.
Characteristic Prior to chemotherapy All patients
(N=260) (N=876)
Age, y, mean (SD) 63 (10) 64 (11)
Male, n (%) 156 (60) 516 (59)
Body Mass Index
Mean (SD), kg/m2 25 (4.3) 25 (4)
>35 kg/m2, n (%) 7 (2.7) 27 (3.1)
WHO performance status ≥2, n (%) 25 (9.6) 79 (8)
Previous VTE, n (%) 3 (1.2) 13 (1.5)
Antiplatelet therapy, n (%) 26 (10) 109 (12)
Tumor type, n (%)
Lung 73 (28) 224 (26)
Esophagus 47 (18) 170 (19)
Colorectal 50 (19) 158 (18)
Pancreas 36 (14) 109 (12)
Breast 18 (6.9) 82 (9.4)
Prostate 11 (4.2) 41 (4.7)
Gastric 16 (6.2) 40 (4.6)
Ovarian 7 (2.7) 39 (4.5)
Bladder 2 (0.8) 13 (1.5)
Distant metastasis, n (%) 179 (69) 581 (66)
Gemcitabine, n (%) 34 (13) 132 (15)
Platinum-based chemotherapy, n (%) 157 (60) 518 (59)
Erythropoietin stimulating agents, n (%) 21 (8.1) 58 (6.6)
Pre-chemotherapy hemoglobin <10 g/dL, n (%) 15 (5.8) 64 (7.3)
Pre-chemotherapy white blood cell count >11 x 109/L, n (%) 45 (17) 141 (16)
Pre-chemotherapy platelet count ≥350 x 109/L, n (%) 67 (26) 229 (26)
D-dimer >1.44 mg/L 76 (29) 274 (31)
Soluble P-selectin >53.1 ng/L 33 (13) 87 (9.9)
y: years;  SD: Standard Deviation;  VTE: venous thromboembolism;  N, n: number; WHO: World Health Organization.
teristics of the patients enrolled prior to chemotherapy
and the complete study group are summarized in Table 2.
No significant differences were found between patients
enrolled prior to chemotherapy and those enrolled during
chemotherapy, except for higher P-selectin levels in the
former group. The distribution of the scores are summa-
rized in Online Supplementary Appendix text 2. Multiple
imputation was used to calculate the Khorana in 33
patients (4%), the Vienna CATS score in 134 patients
(15%), the PROTECHT score in 38 patients (4%), and the
CONKO score in 47 patients (5%), in whom data on one
or more of the score items were missing. 
Overall, 53 patients (6.1%) developed VTE during the 6-
month follow-up period, of whom 27 only had PE  (3.1%),
15 had proximal DVT (1.7%), 7 had UEDVT  (0.8%), 3
had PE and DVT (0.3%), and one had  isolated distal DVT
(0.1%). The corresponding cumulative incidence in the
competing risks analysis was 6.5% (95%CI: 4.9-8.3%) at
180 days. VTE was symptomatic in 33 cases (62%). Two
events (3.8%) were fatal. The median time to VTE was 57
days (interquartile range 33-116). Ten patients (1.1%)
were lost to follow up and 163 patients (19%) died. 
Performance of scores
Of the 260 patients who were enrolled prior to
chemotherapy, 20 (7.7%) developed VTE, including 13
symptomatic events. In this group, the area under the
ROC curves for the different scores (reflecting discrimina-
tory performance) ranged from 0.50 (95%CI: 0.44-0.57)
for the CONKO score and 0.50 (95%CI: 0.42-0.57) for the
Khorana score to 0.57 (95%CI: 0.48-0.66) for the Vienna
CATS score (Table 3). At the conventional positivity
threshold of 3 points, the proportion of patients classified
as high-risk ranged from 13% (95%CI: 9.5-18%) for the
Khorana score to 34% (95%CI: 28-40%) for the PRO-
TECHT score (Table 3). The 6-month VTE incidence in
these high-risk patients ranged from 5.2% (95%CI: 0.9-
16%) for the CONKO score to 9.5% (95%CI: 4.4-17%)
for the PROTECHT score (Table 3; see  Figure 1 for time-
to-event curves). At the evaluated positivity thresholds of
2, 3, or 4 points, none of the scores was able to discrimi-
nate between low- and high-risk patients (Online
Supplementary Appendix text 3).
The analyses were repeated in all 876 patients, including
the 616 patients enrolled after the start of chemotherapy
(median 28 days; interquartile range 16-56) for whom
blood counts collected before chemotherapy were used to
calculate the scores. Overall, results were comparable to
the analyses restricted to patients enrolled prior to
chemotherapy. The area under the ROC curves ranged
from 0.52 (95%CI: 0.47-0.58) for the Khorana score to
0.59 (95%CI: 0.52-0.66) for the PROTECHT score (Table
3). At the conventional positivity threshold of 3 points, the
Khorana score again classified 13% (95%CI: 11-15%) as
high-risk, whereas the PROTECHT score classified 35%
of patients (95%CI: 31-38%) as high-risk (Table 3).
Among high-risk patients, the cumulative VTE incidence
at six months ranged from 6.5% (95%CI: 2.8-12%) when
using the Khorana score to 9.6% (95%CI: 6.6-13%) when
using the PROTECHT score (Table 3). Subhazard ratios
N. van Es et al.
1498 haematologica | 2017; 102(9)
Table 3. Performance of different scores in patients enrolled prior to chemotherapy (n=260) and all patients (n=876).
Khorana Vienna CATS PROTECHT CONKO
score score score score
Patients enrolled prior to chemotherapy (n=260)
Time-dependent c-index at 180 days (95% CI) 0.50 0.57 0.54 0.50
(0.42-0.57) (0.48-0.66) (0.45-0.63) (0.44-0.57)
High-risk patients (≥3 points), % (95% CI) 13 31 34 15 
(9.5-18) (26-37) (28-40) (11-20)
6-month VTE risk in low-risk patients (≤2 points), % (95% CI) 8.4 7.9 7.4 8.6
(5.1-13) (4.4-13) (4.0-12) (5.3-13)
6-month VTE risk in high-risk patients (≥3 points), % (95% CI) 6.0 8.4 9.5 5.2 
(1.0-18) (3.5-16) (4.4-17) (0.9-16)
Subhazard ratio for high- (≥3 points) vs. low-risk patients (≤2 points) 0.69 1.1 1.3 0.58 
(0.17-2.9) (0.41-2.7) (0.53-3.15) (0.14-2.4)
All patients (n=876)
Time-dependent c-index at 180 days (95% CI) 0.52 0.58 0.59 0.53
(0.47-0.58) (0.51-0.66) (0.52-0.66) (0.47-0.59)
High-risk patients (≥3 points), % (95% CI) 13 27 35 15 
(11-15) (24-30) (31-38) (13-18)
6-month VTE risk in low-risk patients (≤2 points), % (95% CI) 6.5 5.5 4.7 6.4
(4.8-8.4) (3.8-7.6) (3.1-6.8) (4.7-8.4)
6-month VTE risk in high-risk patients (≥3 points), % (95% CI) 6.5 9.1 9.6 7.1 
(2.8-12) (5.8-13) (6.6-13) (3.5-12)
SHR for high- (≥3 points) vs. low-risk patients (≤2 points) 1.0 1.7 2.1 1.1 
(0.46-2.3) (1.0-3.1) (1.2-3.6) (0.56-2.4)
CI: Confidence Interval; SHR: subdistribution Hazard Ratio; VTE: venous thromboembolism; vs.: versus; n: number.
for VTE in high- versus low-risk patients ranged from 1.0
(95%CI: 0.46-2.2) for the Khorana score to 1.7 (95%CI:
1.0-3.1) for the Vienna CATS score and 2.1 (95%CI: 1.2-
3.7) for the PROTECHT score (Table 3; see Online
Supplementary Appendix text 4 for time-to-event curves). At
positivity thresholds of 2 or 4 points, the difference in VTE
risk between high- and low-risk patients was not signifi-
cant for any of the scores (Online Supplementary Appendix
text 3). 
Sensitivity analyses
The sensitivity analysis restricted to symptomatic VTE
in the total study group yielded comparable results (Online
Supplementary Appendix text 5). The 6-month risk of symp-
tomatic VTE in high-risk patients ranged from 3.7%
(95%CI: 1.2-8.6%) for the Khorana score to 6.2%
(95%CI: 3.8-9.4%) for the PROTECHT score. 
In the sensitivity analysis restricted to the first 90 days
of follow up, in which 34 of 876 patients (3.9%) devel-
oped VTE, the discriminatory performance of all scores
was slightly better  (Online Supplementary Appendix text 6).
The 90-day VTE incidence in high-risk patients (≥3 points)
ranged from 3.6% (95%CI: 1.2-8.4%) for the Khorana
score to 6.4% (95%CI: 3.7-10%) for the Vienna CATS
score and 6.4% (95%CI: 4.0-9.6%) for the PROTECHT
score. The results from the complete case analysis did not
substantially differ from the analysis of the imputed
datasets  (Online Supplementary Appendix text 7).  
Results of the multivariable analyses are shown in
Online Supplementary Appendix text 8. None of the Khorana
score items were significantly associated with VTE in any
of the scores. In the Vienna CATS score, the dichotomized
D-dimer result was significantly associated with VTE
(SHR 2.4; 95%CI: 1.3-4.4), while in the PROTECHT score,
both gemcitabine (SHR 3.7; 95%CI: 1.8-7.6) and plat-
inum-based chemotherapy (SHR 2.8; 95%CI: 1.4-5.6)
were associated with VTE conditional on the other items.
Discussion
This multinational, prospective cohort study provides a
direct comparison of the performance of four clinical and
biomarker-based prediction scores for VTE in patients
with advanced solid cancer receiving chemotherapy. All
scores had a poor discriminatory performance, although
the Vienna CATS and PROTECHT scores were able to
discriminate between high- and low-risk patients when
used dichotomously in the complete study group. The 6-
month VTE incidence among patients classified as high-
risk by these two scores was approximately 2-fold higher
than in low-risk patients. 
The poor overall discriminatory performance of the
scores could partly be explained by the findings of the
multivariable analysis. Hemoglobin levels, white blood
cell counts, and platelet counts were not significantly asso-
ciated with VTE. In a large prospective cohort study,
Posch and colleagues also showed that the predictive per-
formance of these items was limited,22 thereby question-
ing the relevance of these items for VTE risk prediction in
cancer patients. In addition, in the present study, only 3%
of patients had a BMI over 35 kg/m2, of whom none devel-
oped VTE. The low prevalence of obesity among cancer
patients led Pelzer and colleagues to propose the CONKO
score, in which BMI was replaced with World Health
Organization performance status.10 However, we did not
observe any significant improvement in discriminatory
performance of this modified score compared to the
Khorana score. 
The Vienna CATS and PROTECHT score were the only
two scores that could identify high-risk patients when
used dichotomously. However, this significant association
was observed in the complete study group, but not in
patients enrolled prior to chemotherapy. Since the charac-
teristics of patients enrolled prior to and during
chemotherapy were comparable, possible explanations
include differences in unobserved confounders or impreci-
sion in the estimates. The predictive performance of the
two scores in the complete study group appeared to be
predominantly driven by the predictive performance of D-
dimer levels in the Vienna CATS score and type of
chemotherapy in the PROTECHT score, which could
explain why they performed better than the Khorana and
CONKO scores. Drawbacks of the Vienna CATS score
include measuring D-dimer and soluble P-selectin, which
may be difficult in clinical practice, while the PROTECHT
score is more complex than the Khorana score because
another two items are added. Moreover, the risk of VTE
patients classified as low-risk by these scores was still
appreciable, with 6-month rates of 5-6%, compared to 8-
10% in high-risk patients. 
The Khorana score has already been extensively evalu-
ated in various studies with different patient populations
and duration of follow up. In studies restricting enrollment
to single tumor types, such as pancreatic13,23 and lung can-
cer,12 the Khorana score was often not able to discriminate
between low- and high-risk patients, while other studies
did confirm the score’s predictive ability.8,24,25 In addition,
in the present study, differences in case-mix compared to
the derivation study may partly explain the poor perform-
ance. For example, in the present study, the proportion of
patients with esophageal cancer was higher and 
enrollment was restricted to patients with advanced can-
cer. However, evaluating clinical prediction score in other
settings and populations is the very essence of external
validation studies; a score should maintain its predictive
performance across a broad spectrum of patients, includ-
ing those more recently treated, as well as different geo-
graphical locations, before it can be adopted into clinical
practice.
It has to be noted that the original Khorana score was
derived in a study with a median follow up of only 2.5
months and that not all cancer types were represented.
Whether results should be extrapolated to other tumor
types, and whether clinical and laboratory information
obtained prior to chemotherapy remains predictive
beyond the initial cancer treatment period remains uncer-
tain. This notion was supported by additional analyses, in
which we observed that the area under the time-depen-
dent ROC-curves decreased rapidly during the first weeks
of follow up (data not shown). Similarly, in the sensitivity
analysis restricted to the first three months of follow up,
the discriminatory performance of the dichotomized
Vienna CATS and PROTECHT scores appeared to
improve somewhat compared to the complete follow-up
period.  
The present prospective study is one of the largest in
which multiple prediction scores for cancer-associated
VTE were evaluated in a representative sample of patients
with various tumor types. By restricting enrollment to
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patients with locally advanced or metastatic solid cancers,
the majority of the patients received long-term palliative
rather than short-term neoadjuvant chemotherapy, resem-
bling the populations enrolled in trials evaluating throm-
boprophylaxis in ambulatory cancer patients.26,27 Loss to
follow up was minimal and outcome events were central-
ly verified blinded to the score results to prevent outcome
bias. The multinational design of the study prevented
potential single-center bias and strengthens the external
validity of the findings.28   
Our study has several limitations that merit considera-
tion. We realize that the evaluated prediction scores all
include pre-chemotherapy blood counts, while our study
was designed to also include patients who had recently
started chemotherapy. The main analysis was therefore
restricted to 260 patients who were about to start their
anticancer treatment. For patients who were receiving
chemotherapy at enrollment, retrospectively collected
pre-chemotherapy blood counts were used to calculate
the scores to avoid potential effects of chemotherapy. The
number of events observed in patients enrolled prior to
chemotherapy (n=20) was sufficient to detect potential
differences in VTE incidence between low- and high-risk
patients, although the power may have been somewhat
lower. Given the small difference in VTE risk between
low- and high-risk patients, it is unlikely that a larger sam-
ple of patients enrolled prior to chemotherapy would have
altered our conclusions. 
Along the same line, the enrollment of patients who had
already started chemotherapy may have resulted in
immortal time bias. Since the risk of VTE is usually high-
est in the first months of chemotherapy, the estimate of
the absolute VTE risk may have been conservative. In
addition, if the scores were to have been truly predictive,
the performance of the scores may have been underesti-
mated. However, the findings in the complete study group
were similar (and even slightly better) to those in the
group enrolled prior to chemotherapy.
Sudden deaths were not routinely adjudicated for fatal
PE, although PE was considered to be fatal if autopsy con-
firmed the diagnosis or when PE was objectively con-
firmed prior to death. Still, this approach may have result-
ed in a conservative estimate of the VTE incidence. As the
proportion of such lethal events among all events is often
small, relative risk estimates are unlikely to be affected. 
We realize that the evaluated scores were predominant-
ly derived from observations of symptomatic events.
Since treatment recommendations are similar for inciden-
tal and for symptomatic events, thromboprophylaxis is
just as important to prevent incidental VTE. These events
were, therefore, included in the primary outcome. The
findings of the sensitivity analysis restricted to sympto-
matic events was comparable to those from the overall
analysis, suggesting that the examined scores have similar
performance in predicting incidental events. 
A different D-dimer assay was used in the present study
than in the derivation study of the Vienna CATS score,
which could have impacted on the discriminatory per-
formance of the dichotomous D-dimer result.
Nevertheless, D-dimer was one of the strongest predictors
of VTE in the multivariable analysis, suggesting that the
evaluated threshold of 1.44 mg/L may be a reasonable
one, also for other assays. 
What are the clinical implications of the present findings
and the future steps for using prediction tools for cancer-
associated VTE? A recent Cochrane systematic review
demonstrated that LMWH in prophylactic doses reduces
the relative risk of symptomatic VTE by 46% when com-
pared to no thromboprophylaxis.1 Assuming that these
findings also apply to high-risk patients, the use of the
Vienna CATS or PROTECHT scores to select patients for
thromboprophylaxis could theoretically result in an
absolute risk reduction of approximately 4-5% with  a
score of 20-25 needed in order to decide to start treatment.
Subcutaneous injections for six months can be burden-
some, perhaps even more for oncological patients with a
limited life expectancy. The same Cochrane review also
showed that LMWH thromboprophylaxis was associated
with a non-significant 44% increase in the risk of major
bleeding with a score of 125 needed before treatment is
considered harmful; this should be carefully balanced
against the potential benefits. 
Future studies should aim to refine current risk predic-
tion tools or develop new models in order to further
improve the risk-benefit ratio of thromboprophylaxis in
ambulatory cancer patients. Risk models that take into
account the differences in baseline risk and prognostic fac-
tors across various types of cancer would allow personal-
ized risks to be calculated more precisely by only using
predictors that are relevant for a specific cancer type.
Whether thromboprophylaxis with direct oral anticoagu-
lants is a safe, effective, and less burdensome alternative in
ambulatory cancer patients is currently being investigated
in several ongoing trials that use the Khorana score for risk
stratification (e.g. clinicaltrials.gov identifiers: 02555878 and
02048865). Interestingly, one of the trials applies the
Khorana score at a lower positivity threshold of 2 points,
which classifies a greater proportion of patients in the
high-risk group, but in parallel may decrease the positive
predictive value of the score. 
The present findings do not support the use of any of
the examined scores to select patients for thrombopro-
phylaxis. The discriminatory performance of the
dichotomized Vienna CATS and PROTECHT scores is
somewhat encouraging, but confirmation in subsequent
observational and intervention studies providing throm-
boprophylaxis to high-risk patients is needed before they
can be used in clinical practice. 
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